DK1373502T3 - Dopaminerge neuronale overlevelsesfremmende faktorer og avendelser heraf - Google Patents

Dopaminerge neuronale overlevelsesfremmende faktorer og avendelser heraf

Info

Publication number: DK1373502T3
Authority: DK; Denmark
Prior art keywords: methods; manf; neuronal survival; dopaminergic neuronal; causes
Prior art date: 2001-03-20

Application number

DK02706572.1T

Other languages

English (en)

Inventor

John W Commissiong

Andrei A Raibekas

Original Assignee

Amarantus Therapeutics Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-03-20

Filing date

2002-03-20

Publication date

2011-01-10

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23061211&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1373502(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2002-03-20 Application filed by Amarantus Therapeutics Inc filed Critical Amarantus Therapeutics Inc

2011-01-10 Application granted granted Critical

2011-01-10 Publication of DK1373502T3 publication Critical patent/DK1373502T3/da

Links

230000003291 dopaminomimetic effect Effects 0.000 title abstract 2
230000006576 neuronal survival Effects 0.000 title abstract 2
230000001737 promoting effect Effects 0.000 title 1
238000000034 method Methods 0.000 abstract 4
AVVWPBAENSWJCB-GASJEMHNSA-N D-mannofuranose Chemical compound OC[C@@H](O)[C@H]1OC(O)[C@@H](O)[C@H]1O AVVWPBAENSWJCB-GASJEMHNSA-N 0.000 abstract 3
101000616876 Homo sapiens Mesencephalic astrocyte-derived neurotrophic factor Proteins 0.000 abstract 3
102100021833 Mesencephalic astrocyte-derived neurotrophic factor Human genes 0.000 abstract 3
238000002054 transplantation Methods 0.000 abstract 2
230000004071 biological effect Effects 0.000 abstract 1
210000004027 cell Anatomy 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
230000003278 mimic effect Effects 0.000 abstract 1
230000004770 neurodegeneration Effects 0.000 abstract 1
208000015122 neurodegenerative disease Diseases 0.000 abstract 1
210000002569 neuron Anatomy 0.000 abstract 1
150000007523 nucleic acids Chemical class 0.000 abstract 1
102000039446 nucleic acids Human genes 0.000 abstract 1
108020004707 nucleic acids Proteins 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1
239000000546 pharmaceutical excipient Substances 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5058—Neurological cells

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Zoology (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Gastroenterology & Hepatology (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Biomedical Technology (AREA)
Immunology (AREA)
Epidemiology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Cell Biology (AREA)
Developmental Biology & Embryology (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Biophysics (AREA)
Toxicology (AREA)
Biochemistry (AREA)
Psychology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Virology (AREA)
Biotechnology (AREA)
Ophthalmology & Optometry (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Peptides Or Proteins (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)

DK02706572.1T 2001-03-20 2002-03-20 Dopaminerge neuronale overlevelsesfremmende faktorer og avendelser heraf DK1373502T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US27751601P	2001-03-20	2001-03-20
PCT/CA2002/000373 WO2002074956A2 (en)	2001-03-20	2002-03-20	Dopaminergic neuronal survival-promoting factors and uses thereof

Publications (1)

Publication Number	Publication Date
DK1373502T3 true DK1373502T3 (da)	2011-01-10

Family

ID=23061211

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK02706572.1T DK1373502T3 (da)	2001-03-20	2002-03-20	Dopaminerge neuronale overlevelsesfremmende faktorer og avendelser heraf

Country Status (9)

Country	Link
US (5)	US20020182198A1 (da)
EP (1)	EP1373502B8 (da)
JP (1)	JP2004528835A (da)
AT (1)	ATE485377T1 (da)
CA (1)	CA2441740A1 (da)
DE (1)	DE60238038D1 (da)
DK (1)	DK1373502T3 (da)
ES (1)	ES2353490T3 (da)
WO (1)	WO2002074956A2 (da)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE60238038D1 (de)	2001-03-20	2010-12-02	Cns Protein Therapeutics Inc	Das Überleben dopaminerger Neuronen fördernde Faktoren und deren Verwendungen
US7452969B2 (en) *	2002-08-30	2008-11-18	Licentia Ltd	Neurotrophic factor protein and uses thereof
EP1644406B1 (en)	2003-07-11	2012-08-15	DeveloGen Aktiengesellschaft	Use of dg153 secreted protein products for preventing and treating pancreatic diseases and/or obesity and/or metabolic syndrome
PL1969003T3 (pl) *	2005-12-14	2011-05-31	Herantis Pharma Plc	Zastosowanie białka czynnika neurotroficznego
WO2009120810A2 (en) *	2008-03-25	2009-10-01	Cns Protein Therapeutics, Inc.	Neurodegenerative disorders
FI20080326A0 (fi)	2008-04-30	2008-04-30	Licentia Oy	Neurotroofinen tekijä MANF ja sen käytöt
WO2011038366A1 (en) *	2009-09-25	2011-03-31	Amarantus Therapeutics, Inc.	Dopaminergic selective factors
CA2838818A1 (en) *	2011-06-09	2012-12-13	University Of Miami	Methods of treatment for retinal diseases
FI20115870A0 (fi) *	2011-09-05	2011-09-05	Urmas Arumaee	Neuroprotektiiviset soluihin tunkeutuvat peptidit
EP2820424B1 (en) *	2012-01-24	2016-12-07	University of Massachusetts	Soluble manf in pancreatic beta-cell disorders
EP3122370A1 (en) *	2014-03-28	2017-02-01	Buck Institute for Research on Aging	Methods and compositions for modulating the immune system
US20190192629A1 (en) *	2015-11-18	2019-06-27	Herantis Pharma Plc	Compositions Comprising CDNF or MANF for use in the Intranasal Treatment of Central Nervous System Diseases
EP3774858B1 (en) *	2018-03-29	2025-07-30	MyNeuroCure Oy	C-terminal cdnf fragments having neuroprotective effect
CN113292656B (zh) *	2020-02-21	2022-10-25	四川大学华西医院	用于防治肥胖的中脑星形胶质细胞源性神经营养因子的融合蛋白

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2001019851A2 (en) *	1999-09-16	2001-03-22	Neurotrophic Bioscience Inc.	Opaminergic neuronal survival-promoting factors and uses thereof
EP1225224A4 (en) *	1999-10-01	2004-03-24	Kyowa Hakko Kogyo Kk	DNA THE SHEAR RESPONSE
AU2001250912B2 (en) *	2000-03-21	2007-01-04	Curagen Corporation	VEGF-modulated genes and methods employing them
DE60238038D1 (de)	2001-03-20	2010-12-02	Cns Protein Therapeutics Inc	Das Überleben dopaminerger Neuronen fördernde Faktoren und deren Verwendungen
EP1373314A2 (en) *	2001-03-30	2004-01-02	Geneprot, Inc.	Human arginine-rich protein-related compositions
WO2002090541A1 (en) *	2001-05-03	2002-11-14	Murdoch Childrens Research Institute	Determination of a genetic predisposition for behavioural disorders
GB0113657D0 (en) *	2001-06-05	2001-07-25	Geneprot Inc	Improved native chemical ligation with three or more components
US7452969B2 (en)	2002-08-30	2008-11-18	Licentia Ltd	Neurotrophic factor protein and uses thereof
US20060195915A1 (en)	2002-08-30	2006-08-31	Licentia Ltd.	Novel neurotrophic factor protein and uses thereof
WO2009120810A2 (en)	2008-03-25	2009-10-01	Cns Protein Therapeutics, Inc.	Neurodegenerative disorders
FI20080326A0 (fi)	2008-04-30	2008-04-30	Licentia Oy	Neurotroofinen tekijä MANF ja sen käytöt
CA2838818A1 (en)	2011-06-09	2012-12-13	University Of Miami	Methods of treatment for retinal diseases

2002
- 2002-03-20 DE DE60238038T patent/DE60238038D1/de not_active Expired - Lifetime
- 2002-03-20 US US10/102,265 patent/US20020182198A1/en not_active Abandoned
- 2002-03-20 CA CA002441740A patent/CA2441740A1/en not_active Abandoned
- 2002-03-20 WO PCT/CA2002/000373 patent/WO2002074956A2/en not_active Ceased
- 2002-03-20 JP JP2002574347A patent/JP2004528835A/ja active Pending
- 2002-03-20 DK DK02706572.1T patent/DK1373502T3/da active
- 2002-03-20 AT AT02706572T patent/ATE485377T1/de not_active IP Right Cessation
- 2002-03-20 ES ES02706572T patent/ES2353490T3/es not_active Expired - Lifetime
- 2002-03-20 EP EP02706572A patent/EP1373502B8/en not_active Expired - Lifetime
2009
- 2009-08-04 US US12/535,029 patent/US8084425B2/en not_active Expired - Fee Related
2011
- 2011-11-28 US US13/305,025 patent/US9115208B2/en not_active Expired - Fee Related
2015
- 2015-06-30 US US14/755,272 patent/US20160152673A1/en not_active Abandoned
2017
- 2017-02-27 US US15/443,712 patent/US20170298110A1/en not_active Abandoned

Also Published As

Publication number	Publication date
US20100119491A1 (en)	2010-05-13
US9115208B2 (en)	2015-08-25
EP1373502B1 (en)	2010-10-20
US20020182198A1 (en)	2002-12-05
ES2353490T3 (es)	2011-03-02
WO2002074956A3 (en)	2003-07-10
CA2441740A1 (en)	2002-09-26
US8084425B2 (en)	2011-12-27
US20170298110A1 (en)	2017-10-19
EP1373502A2 (en)	2004-01-02
EP1373502B8 (en)	2010-12-22
DE60238038D1 (de)	2010-12-02
JP2004528835A (ja)	2004-09-24
ATE485377T1 (de)	2010-11-15
US20130078220A1 (en)	2013-03-28
WO2002074956A2 (en)	2002-09-26
US20160152673A1 (en)	2016-06-02

Publication	Publication Date	Title
BRPI0412845A (pt)	2006-09-26	herpes-vìrus, uso de um vìrus, composição farmacêutica, e, método de tratamento de um tumor em um indivìduo em necessidade do mesmo
ATE485377T1 (de)	2010-11-15	Das überleben dopaminerger neuronen fördernde faktoren und deren verwendungen
ES2170104T3 (es)	2002-08-01	Inhibidores de la produccion de proteinas de beta-amiloide.
DE602004020263D1 (de)	2009-05-07	Amino-substituierte diaryläa,dücyclohepten- analoga als muscarinische agonisten und verfahren zur behandlung von neuropsychiatrischen erkrankungen
BRPI0015533B8 (pt)	2021-05-25	enzima alfa-l-iduronidase humana recombinante, composição farmacêutica compreendendo a mesma e método para sua purificação
BRPI0407662B8 (pt)	2021-05-25	derivados do ácido 1-fenilalcanocarboxílico para o tratamento de doenças neurodegenerativas
ATE490786T1 (de)	2010-12-15	Behandlung von verletzungen des zentralen nervensystems
ATE229806T1 (de)	2003-01-15	Wirkstoff zur behandlung neurodegenerativer störungen
IL136690A0 (en)	2001-06-14	Inhibition of raf kinase using symmetrical and unsymmetrical substituted diphenyl ureas
NO20004803L (no)	2000-11-27	Smilagening og anzurogenin for behandling av Alzheimers sykdom
DE60216830D1 (de)	2007-02-01	Pharmazeutische Zusammensetzungen zur Behandlung von Störungen des ZNS oder anderen Erkrankungen
EA200401365A1 (ru)	2005-04-28	Способы лечения илеуса
ATE300052T1 (de)	2005-08-15	Verwendung von radioliganden zum screening von inhibitoren der herstellung von beta-amyloid peptiden
NO20092741L (no)	2009-09-21	DR6-antagonister og anvendelse derav ved behandling av neurologiske forstyrrelser
ATE311476T1 (de)	2005-12-15	Polymorphismen im gen für den humanen organischen anionentransporter c (oatp-c)
WO2001019851A3 (en)	2001-09-20	Opaminergic neuronal survival-promoting factors and uses thereof
ATE348158T1 (de)	2007-01-15	Neuartiges collectin
PT1255734E (pt)	2006-09-29	Derivados de isatina com actividade neurotrofica
ATE548048T1 (de)	2012-03-15	Oncomodulin zur behandlung von neurologishen erkrankungen
BR0314541A (pt)	2005-07-26	Tratamento de demência e doença de parkinson
ATE391915T1 (de)	2008-04-15	Verwendung des proteins grf-1 zur auswahl von molekülen
DE60004093D1 (de)	2003-08-28	Pharmazeutische zusammensetzung welche riluzol und gabapentin enthält zur behandung von motoneuronalen krankheiten
SE9902489D0 (sv)	1999-06-30	Mutated Nurr1 gene
DE60224778D1 (de)	2008-03-13	Zusammensetzungen und Verfahren zur Behandlung und zur Detektion von proliferativen Störungen die mit der Überexpression des menschlichen "Transketolase like-1" gens in Zusammenhang stehen
ATE397753T1 (de)	2008-06-15	Screening-verfahren für eine prophylaktische und therapeutische substanz für eine nierenerkrankung